Potential benefits of cell therapy in coronary heart disease

Journal of Cardiology

Volumn 62, Issue 5, 2013, Pages 267-276

  Grimaldi, Vincenzo ^a   Mancini, Francesco Paolo ^b   Casamassimi, Amelia ^a   Al Omran, Mohammed ^c   Zullo, Alberto ^b,d   Infante, Teresa ^e   Napoli, Claudio ^a,e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF SANNIO   (Italy)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e IRCCS SDN   (Italy)

Author keywords

Cell delivery; Cell therapy; Clinical trials; Coronary heart disease; Stem cells

Indexed keywords

ACUTE HEART INFARCTION; ADULT STEM CELL; CELL HOMING; CELL POPULATION; CELL REGENERATION; CELL SURVIVAL; CELL THERAPY; CELL TRANSDIFFERENTIATION; CELL TYPE; CENTRAL VENOUS CATHETER; CONGESTIVE HEART FAILURE; CORONARY ARTERY INJECTION; CORONARY VEIN; EMBRYONIC STEM CELL; ENDOCARDIUM; EPICARDIUM; EPIGENETICS; FETAL STEM CELL; FIBROBLAST; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEMATOPOIETIC STEM CELL; HUMAN; IMAGING SYSTEM; INJECTION SITE; INTRAMYOCARDIAL INJECTION; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MYOBLAST; NONHUMAN; NONISCHEMIC CARDIOMYOPATHY; PARACRINE SIGNALING; PATIENT SAFETY; PLURIPOTENT STEM CELL; PRODUCT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATIVE MEDICINE; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMIC INTRAVENOUS INJECTION; TISSUE ENGINEERING; TREATMENT OUTCOME;

CELL DELIVERY; CELL THERAPY; CLINICAL TRIALS; CORONARY HEART DISEASE; STEM CELLS;

ANIMALS; CELL ENGINEERING; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; HUMANS; MOLECULAR IMAGING; PARACRINE COMMUNICATION; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

EID: 84887185268     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.05.017     Document Type: Review

References (102)

1. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., Ferguson T.B., Ford E., Furie K., Gillespie C., Go A., Greenlund K., Haase N., Hailpern S., Ho P.M., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
2. Heusch G. SCIPIO brings new momentum to cardiac cell therapy. Lancet 2011, 378:1827-1828.
3. Porrello E.R., Mahmoud A.I., Simpson E., Hill J.A., Richardson J.A., Olson E.N., Sadek H.A. Transient regenerative potential of the neonatal mouse heart. Science 2011, 331:1078-1080.
4. Anversa P., Leri A., Rota M., Hosoda T., Bearzi C., Urbanek K., Kajstura J., Bolli R. Concise review: stem cells, myocardial regeneration, and methodological artifacts. Stem Cells 2007, 25:589-601.
5. He X.-Z., Wang H.-Y., Shen Y., Zhong Q.-H., Fang S.-X., Peng W.-J., Xue J.-F. Cardiomyocyte progenitors in a canine pulmonary vein model of persistent atrial fibrillation. J Cardiol 2012, 60:242-247.
6. Mahmood A., Napoli C., Aldahmash A. In vitro differentiation and maturation of human embryonic stem cell into multipotent cells. Stem Cells Int 2011, 735420.
7. Segers V.F., Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008, 451:937-942.
8. Yamada S., Nelson T.J., Crespo-Diaz R.J., Perez-Terzic C., Liu X.K., Miki T., Seino S., Behfar A., Terzic A. Embryonic stem cell therapy of heart failure in genetic cardiomyopathy. Stem Cells 2008, 26:2644-2653.
9. Balestrieri M.L., Lu S.J., de Nigris F., Giovane A., Williams-Ignarro S., D'Armiento F.P., Feng Q., Fiorito C., Testa G., Pastore L., Cacciatore F., Mancini F.P., Servillo L., De Rosa G., Pagliarulo C., et al. Therapeutic angiogenesis in diabetic apolipoprotein E-deficient mice using bone marrow cells, functional hemangioblasts and metabolic intervention. Atherosclerosis 2010, 209:403-414.
10. Xue T., Cho H.C., Akar F.G., Tsang S.Y., Jones S.P., Marbán E., Tomaselli G.F., Li R.A. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation 2005, 111:11-20.
11. Ramkisoensing A.A., Pijnappels D.A., Askar S.F., Passier R., Swildens J., Goumans M.J., Schutte C.I., de Vries A.A., Scherjon S., Mummery C.L., Schalij M.J., Atsma D.E. Human embryonic and fetal mesenchymal stem cells differentiate toward three different cardiac lineages in contrast to their adult counterparts. PLoS ONE 2011, 6:e24164.
12. Flynn A., O'Brien T. Stem cell therapy for cardiac disease. Expert Opin Biol Ther 2011, 11:177-187.
13. Sanganalmath S.K., Abdel-Latif A., Bolli R., Xuan Y.T., Dawn B. Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond. Basic Res Cardiol 2011, 106:709-733.
14. Zhao Q., Sun C., Xu X., Zhou J., Wu Y., Tian Y., Ma A., Liu Z. Early use of granulocyte colony stimulating factor improves survival in a rabbit model of chronic myocardial ischemia. J Cardiol 2013, 61:87-94.
15. Napoli C., Hayashi T., Cacciatore F., Casamassimi A., Casini C., Al-Omran M., Ignarro L.J. Endothelial progenitor cells as therapeutic agents in the microcirculation: an update. Atherosclerosis 2011, 215:9-22.
16. Casamassimi A., Grimaldi V., Infante T., Al-Omran M., Crudele V., Napoli C. Adult stem cells and the clinical arena: are we able to widely use this therapy in patients with chronic limbs arteriopathy and ischemic ulcers without possibility of revascularization. Cardiovasc Hematol Agents Med Chem 2012, 10:99-108.
17. Williams A.R., Hare J.M. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011, 109:923-940.
18. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., Gerstenblith G., DeMaria A.N., Denktas A.E., Gammon R.S., Hermiller J.B., Reisman M.A., Schaer G.L., Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286.
19. Kuroda Y., Kitada M., Wakao S., Dezawa M. Bone marrow mesenchymal cells: how do they contribute to tissue repair and are they really stem cells?. Arch Immunol Ther Exp (Warsz) 2011, 59:369-378.
20. Bieback K., Wuchter P., Besser D., Franke W., Becker M., Ott M., Pacher M., Ma N., Stamm C., Klüter H., Müller A., Ho A.D. START-MSC consortium. Mesenchymal stromal cells (MSCs): science and f(r)iction. J Mol Med (Berl) 2012, 90:773-782.
21. Shi C. Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells. Immunology 2012, 136:133-138.
22. Wang S., Qu X., Zhao R.C. Mesenchymal stem cells hold promise for regenerative medicine. Front Med 2011, 5:372-378.
23. Abdel-Latif A., Bolli R., Tleyjeh I.M., Montori V.M., Perin E.C., Hornung C.A., Zuba-Surma E.K., Al-Mallah M., Dawn B. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007, 167:989-997.
24. Menasché P. Skeletal myoblasts as a therapeutic agent. Prog Cardiovasc Dis 2007, 50:7-17.
25. Menasché P., Alfieri O., Janssens S., McKenna W., Reichenspurner H., Trinquart L., Vilquin J.T., Marolleau J.P., Seymour B., Larghero J., Lake S., Chatellier G., Solomon S., Desnos M., Hagège A.A. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008, 117:1189-1200.
26. Siminiak T., Fiszer D., Jerzykowska O., Grygielska B., Rozwadowska N., Kałmucki P., Kurpisz M. Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial. Eur Heart J 2005, 26:1188-1195.
27. Dib N., Dinsmore J., Lababidi Z., White B., Moravec S., Campbell A., Rosenbaum A., Seyedmadani K., Jaber W.A., Rizenhour C.S., Diethrich E. One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). JACC Cardiovasc Interv 2009, 2:9-16.
28. Gavira J.J., Herreros J., Perez A., Garcia-Velloso M.J., Barba J., Martin-Herrero F., Cañizo C., Martin-Arnau A., Martí-Climent J.M., Hernández M., López-Holgado N., González-Santos J.M., Martín-Luengo C., Alegria E., Prósper F. Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up. J Thorac Cardiovasc Surg 2006, 131:799-804.
29. Menasché P. Towards the second generation of skeletal myoblasts. Cardiovasc Res 2008, 79:355-356.
30. Gonçalves L.M. Stem cell therapy for cardiovascular diseases: are we still at the beginning of a long road. Cardiovasc Hematol Disord Drug Targets 2010, 10:158-160.
31. Bollini S., Smart N., Riley P.R. Resident cardiac progenitor cells: at the heart of regeneration. J Mol Cell Cardiol 2011, 50:296-303.
32. Urbanek K., Torella D., Sheikh F., De Angelis A., Nurzynska D., Silvestri F., Beltrami C.A., Bussani R., Beltrami A.P., Quaini F., Bolli R., Leri A., Kajstura J., Anversa P. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci USA 2005, 102:8692-8697.
33. Bolli R., Chugh A.R., D'Amario D., Loughran J.H., Stoddard M.F., Ikram S., Beache G.M., Wagner S.G., Leri A., Hosoda T., Sanada F., Elmore J.B., Goichberg P., Cappetta D., Solankhi N.K., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011, 378:1847-1857.
34. Makkar R.R., Smith R.R., Cheng K., Malliaras K., Thomson L.E., Berman D., Czer L.S., Marbán L., Mendizabal A., Johnston P.V., Russell S.D., Schuleri K.H., Lardo A.C., Gerstenblith G., Marbán E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomized phase 1 trial. Lancet 2012, 379:895-904.
35. Loffredo F.S., Steinhauser M.L., Gannon J., Lee R.T. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011, 8:389-398.
36. Hochedlinger K., Jaenisch R. Nuclear reprogramming and pluripotency. Nature 2006, 441:1061-1067.
37. Jaenisch R., Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 2008, 132:567-582.
38. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
39. Sidhu K.S. New approaches for the generation of induced pluripotent stem cells. Expert Opin Biol Ther 2011, 11:569-579.
40. Rizzi R., Di Pasquale E., Portararo P., Papait R., Cattaneo P., Latronico M.V., Altomare C., Sala L., Zaza A., Hirsch E., Naldini L., Condorelli G., Bearzi C. Post-natal cardiomyocytes can generate iPS cells with an enhanced capacity toward cardiomyogenic re-differentiation. Cell Death Differ 2012, 19:1162-1174.
41. Zhou Y., Kim J., Yuan X., Braun T. Epigenetic modifications of stem cells: a paradigm for the control of cardiac progenitor cells. Circ Res 2011, 109:1067-1081.
42. Klattenhoff C.A., Scheuermann J.C., Surface L.E., Bradley R.K., Fields P.A., Steinhauser M.L., Ding H., Butty V.L., Torrey L., Haas S., Abo R., Tabebordbar M., Lee R.T., Burge C.B., Boyer L.A. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 2013, 152:570-583.
43. Efe J.A., Hilcove S., Kim J., Zhou H., Ouyang K., Wang G., Chen J., Ding S. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol 2011, 13:215-222.
44. Lunde K., Solheim S., Aakhus S., Arnesen H., Abdelnoor M., Egeland T., Endresen K., Ilebekk A., Mangschau A., Fjeld J.G., Smith H.J., Taraldsrud E., Grøgaard H.K., Bjørnerheim R., Brekke M., et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006, 355:1199-1209.
45. Lunde K., Solheim S., Forfang K., Arnesen H., Brinch L., Bjørnerheim R., Ragnarsson A., Egeland T., Endresen K., Ilebekk A., Mangschau A., Aakhus S. Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months' follow-up. J Am Coll Cardiol 2008, 51:674-676.
46. Beitnes J.O., Hopp E., Lunde K., Solheim S., Arnesen H., Brinchmann J.E., Forfang K., Aakhus S. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart 2009, 95:1983-1989.
47. Janssens S., Dubois C., Bogaert J., Theunissen K., Deroose C., Desmet W., Kalantzi M., Herbots L., Sinnaeve P., Dens J., Maertens J., Rademakers F., Dymarkowski S., Gheysens O., Van Cleemput J., et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006, 367:113-121.
48. Assmus B., Honold J., Schächinger V., Britten M.B., Fischer-Rasokat U., Lehmann R., Teupe C., Pistorius K., Martin H., Abolmaali N.D., Tonn T., Dimmeler S., Zeiher A.M. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006, 355:1222-1232.
49. Assmus B., Schächinger V., Teupe C., Britten M., Lehmann R., Döbert N., Grünwald F., Aicher A., Urbich C., Martin H., Hoelzer D., Dimmeler S., Zeiher A.M. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002, 106:3009-3017.
50. Schächinger V., Assmus B., Britten M.B., Honold J., Lehmann R., Teupe C., Abolmaali N.D., Vogl T.J., Hofmann W.K., Martin H., Dimmeler S., Zeiher A.M. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004, 44:1690-1699.
51. Leistner D.M., Fischer-Rasokat U., Honold J., Seeger F.H., Schächinger V., Lehmann R., Martin H., Burck I., Urbich C., Dimmeler S., Zeiher A.M., Assmus B. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol 2011, 100:925-934.
52. Wollert K.C., Meyer G.P., Lotz J., Ringes-Lichtenberg S., Lippolt P., Breidenbach C., Fichtner S., Korte T., Hornig B., Messinger D., Arseniev L., Hertenstein B., Ganser A., Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364:141-148.
53. Meyer G.P., Wollert K.C., Lotz J., Steffens J., Lippolt P., Fichtner S., Hecker H., Schaefer A., Arseniev L., Hertenstein B., Ganser A., Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (Bone marrow transfer to enhance ST elevation infarct regeneration) trial. Circulation 2006, 113:1287-1294.
54. Meyer G.P., Wollert K.C., Lotz J., Pirr J., Rager U., Lippolt P., Hahn A., Fichtner S., Schaefer A., Arseniev L., Ganser A., Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009, 30:2978-2984.
55. Schächinger V., Erbs S., Elsässer A., Haberbosch W., Hambrecht R., Hölschermann H., Yu J., Corti R., Mathey D.G., Hamm C.W., Süselbeck T., Assmus B., Tonn T., Dimmeler S., Zeiher A.M. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221. REPAIR-AMI Investigators.
56. Schächinger V., Erbs S., Elsässer A., Haberbosch W., Hambrecht R., Hölschermann H., Yu J., Corti R., Mathey D.G., Hamm C.W., Süselbeck T., Werner N., Haase J., Neuzner J., Germing A., et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006, 27:2775-2783. REPAIR-AMI Investigators.
57. Assmus B., Rolf A., Erbs S., Elsässer A., Haberbosch W., Hambrecht R., Tillmanns H., Yu J., Corti R., Mathey D.G., Hamm C.W., Süselbeck T., Tonn T., Dimmeler S., Dill T., et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010, 3:89-96. REPAIR-AMI Investigators.
58. Seth S., Narang R., Bhargava B., Ray R., Mohanty S., Gulati G., Kumar L., Reddy K.S., Venugopal P. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial. J Am Coll Cardiol 2006, 48:2350-2351. AIIMS Cardiovascular Stem Cell Study Group.
59. Penicka M., Horak J., Kobylka P., Pytlik R., Kozak T., Belohlavek O., Lang O., Skalicka H., Simek S., Palecek T., Linhart A., Aschermann M., Widimsky P. Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction: a prematurely terminated randomized study. J Am Coll Cardiol 2007, 49:2373-2374.
60. Herbots L., D'hooge J., Eroglu E., Thijs D., Ganame J., Claus P., Dubois C., Theunissen K., Bogaert J., Dens J., Kalantzi M., Dymarkowski S., Bijnens B., Belmans A., Boogaerts M., et al. Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study. Eur Heart J 2009, 30:662-670.
61. Plewka M., Krzemińska-Pakuła M., Lipiec P., Peruga J.Z., Jezewski T., Kidawa M., Wierzbowska-Drabik K., Korycka A., Robak T., Kasprzak J.D. Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction. Am J Cardiol 2009, 104:1336-1342.
62. Tendera M., Wojakowski W., Ruzyłło W., Chojnowska L., Kepka C., Tracz W., Musiałek P., Piwowarska W., Nessler J., Buszman P., Grajek S., Breborowicz P., Majka M., Ratajczak M.Z. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009, 30:1313-1321. REGENT Investigators.
63. Fischer-Rasokat U., Assmus B., Seeger F.H., Honold J., Leistner D., Fichtlscherer S., Schächinger V., Tonn T., Martin H., Dimmeler S., Zeiher A.M. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail 2009, 2:417-423.
64. Strauer B.E., Yousef M., Schannwell C.M. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail 2010, 12:721-729.
65. Diederichsen A.C., Møller J.E., Thayssen P., Videbaek L., Saekmose S.G., Barington T., Kassem M. Changes in left ventricular filling patterns after repeated injection of autologous bone marrow cells in heart failure patients. Scand Cardiovasc J 2010, 44:139-145.
66. Traverse J.H., McKenna D.H., Harvey K., Jorgenso B.C., Olson R.E., Bostrom N., Kadidlo D., Lesser J.R., Jagadeesan V., Garberich R., Henry T.D. Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction. Am Heart J 2010, 160:428-434.
67. Quyyumi A.A., Waller E.K., Murrow J., Esteves F., Galt J., Oshinski J., Lerakis S., Sher S., Vaughan D., Perin E., Willerson J., Kereiakes D., Gersh B.J., Gregory D., Werner A., et al. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J 2011, 161:98-105.
68. Wöhrle J., Merkle N., Mailänder V., Nusser T., Schauwecker P., von Scheidt F., Schwarz K., Bommer M., Wiesneth M., Schrezenmeier H., Hombach V. Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol 2010, 105:804-812.
69. Colombo A., Castellani M., Piccaluga E., Pusineri E., Palatresi S., Longari V., Canzi C., Sacchi E., Rossi E., Rech R., Gerundini P., Viecca M., Deliliers G.L., Rebulla P., Soligo D., et al. Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial. J Cardiovasc Med (Hagerstown) 2011, 12:239-248.
70. Hu S., Liu S., Zheng Z., Yuan X., Li L., Lu M., Shen R., Duan F., Zhang X., Li J., Liu X., Song Y., Wang W., Zhao S., He Z., et al. Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: a single-center, randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 2011, 57:2409-2415.
71. Roncalli J., Mouquet F., Piot C., Trochu J.N., Le Corvoisier P., Neuder Y., Le Tourneau T., Agostini D., Gaxotte V., Sportouch C., Galinier M., Crochet D., Teiger E., Richard M.J., Polge A.S., et al. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J 2011, 32:1748-1757.
72. Traverse J.H., Henry T.D., Ellis S.G., Pepine C.J., Willerson J.T., Zhao D.X., Forder J.R., Byrne B.J., Hatzopoulos A.K., Penn M.S., Perin E.C., Baran K.W., Chambers J., Lambert C., Raveendran G., et al. Cardiovascular Cell Therapy Research Network. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2-3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011, 306:2110-2119.
73. Patel A.N., Geffner L., Vina R.F., Saslavsky J., Urschel H.C., Kormos R., Benetti F. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J Thorac Cardiovasc Surg 2005, 130:1631-1638.
74. Hendrikx M., Hensen K., Clijsters C., Jongen H., Koninckx R., Bijnens E., Ingels M., Jacobs A., Geukens R., Dendale P., Vijgen J., Dilling D., Steels P., Mees U., Rummens J.L. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation 2006, 114(Suppl. 1):I101-I107.
75. Mocini D., Staibano M., Mele L., Giannantoni P., Menichella G., Colivicchi F., Sordini P., Salera P., Tubaro M., Santini M. Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting. Am Heart J 2006, 151:192-197.
76. Stamm C., Kleine H.D., Choi Y.H., Dunkelmann S., Lauffs J.A., Lorenzen B., David A., Liebold A., Nienaber C., Zurakowski D., Freund M., Steinhoff G. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg 2007, 133:717-725.
77. Zhao Q., Sun Y., Xia L., Chen A., Wang Z. Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery. Ann Thorac Surg 2008, 86:1833-1840.
78. Akar A.R., Durdu S., Arat M., Kilickap M., Kucuk N.O., Arslan O., Kuzu I., Ozyurda U. Five-year follow-up after transepicardial implantation of autologous bone marrow mononuclear cells to ungraftable coronary territories for patients with ischaemic cardiomyopathy. Eur J Cardiothorac Surg 2009, 36:633-643.
79. Chan C.W., Kwong Y.L., Kwong R.Y., Lau C.P., Tse H.F. Improvement of myocardial perfusion reserve detected by cardiovascular magnetic resonance after direct endomyocardial implantation of autologous bone marrow cells in patients with severe coronary artery disease. J Cardiovasc Magn Reson 2010, 12:6.
80. Fuchs S., Kornowski R., Weisz G., Satler L.F., Smits P.C., Okubagzi P., Baffour R., Aggarwal A., Weissman N.J., Cerqueira M., Waksman R., Serrruys P., Battler A., Moses J.W., Leon M.B., et al. Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol 2006, 97:823-829.
81. Briguori C., Reimers B., Sarais C., Napodano M., Pascotto P., Azzarello G., Bregni M., Porcellini A., Vinante O., Zanco P., Peschle C., Condorelli G., Colombo A. Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. Am Heart J 2006, 151:674-680.
82. de la Fuente L.M., Stertzer S.H., Argentieri J., Peñaloza E., Miano J., Koziner B., Bilos C., Altman P.A. Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study). Am Heart J 2007, 154. 79e71-7.
83. Tse H.F., Thambar S., Kwong Y.L., Rowlings P., Bellamy G., McCrohon J., Thomas P., Bastian B., Chan J.K., Lo G., Ho C.L., Chan W.S., Kwong R.Y., Parker A., Hauser T.H., et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J 2007, 28:2998-3005.
84. van Ramshorst J., Bax J.J., Beeres S.L., Dibbets-Schneider P., Roes S.D., Stokkel M.P., de Roos A., Fibbe W.E., Zwaginga J.J., Boersma E., Schalij M.J., Atsma D.E. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 2009, 301:1997-2004.
85. Perin E.C., Silva G.V., Henry T.D., Cabreira-Hansen M.G., Moore W.H., Coulter S.A., Herlihy J.P., Fernandes M.R., Cheong B.Y., Flamm S.D., Traverse J.H., Zheng Y., Smith D., Shaw S., Westbrook L., et al. A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011, 161:1078-1087.
86. Perin E.C., Willerson J.T., Pepine C.J., Henry T.D., Ellis S.G., Zhao D.X., Silva G.V., Lai D., Thomas J.D., Kronenberg M.W., Martin A.D., Anderson R.D., Traverse J.H., Penn M.S., Anwaruddin S., et al. Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012, 307:1717-1726.
87. Barbash I.M., Chouraqui P., Baron J., Feinberg M.S., Etzion S., Tessone A., Miller L., Guetta E., Zipori D., Kedes L.H., Kloner R.A., Leor J. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003, 108:863-868.
88. Leistner D., Assmus B., Erbs S., Hambrecht R., Thiele H., Elsaesser A., Dill T., Hamm C., Haberbosch W., Sedding D., Yu J., Corti R., Mathey D., Sueselbeck T., Barth C., et al. Intracoronary infusion of bone marrow-derived mononuclear cells in acute myocardial infarction: 5 year clinical outcome and MRI data of the randomized, double-blind, placebo-controlled REPAIR-AMI Trial. Circulation 2011, 124:A13940.
89. Wu K.H., Han Z.C., Mo X.M., Zhou B. Cell delivery in cardiac regenerative therapy. Ageing Res Rev 2012, 11:32-40.
90. Silva S.A., Sousa A.L., Haddad A.F., Azevedo J.C., Soares V.E., Peixoto C.M., Soares A.J., Issa A.F., Felipe L.R., Branco R.V., Addad J.A., Moreira R.C., Tuche F.A., Mesquita C.T., Drumond C.C., et al. Autologous bone-marrow mononuclear cell transplantation after acute myocardial infarction: comparison of two delivery techniques. Cell Transplant 2009, 18:343-352.
91. Freyman T., Polin G., Osman H., Crary J., Lu M., Cheng L., Palasis M., Wilensky R.L. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006, 27:1114-1122.
92. Seeger F.H., Tonn T., Krzossok N., Zeiher A.M., Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007, 28:766-772.
93. Hofmann M., Wollert K.C., Meyer G.P., Menke A., Arseniev L., Hertenstein B., Ganser A., Knapp W.H., Drexler H. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005, 111:2198-2202.
94. Terrovitis J., Lautamäki R., Bonios M., Fox J., Engles J.M., Yu J., Leppo M.K., Pomper M.G., Wahl R.L., Seidel J., Tsui B.M., Bengel F.M., Abraham M.R., Marbán E. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol 2009, 54:1619-1626.
95. Suzuki K., Murtuza B., Beauchamp J.R., Brand N.J., Barton P.J., Varela-Carver A., Fukushima S., Coppen S.R., Partridge T.A., Yacoub M.H. Role of interleukin-1beta in acute inflammation and graft death after cell transplantation to the heart. Circulation 2004, 110(Suppl. 1):II219-II224.
96. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008, 103:1204-1219.
97. Chavakis E., Dimmeler S. Homing of progenitor cells to ischemic tissues. Antioxid Redox Signal 2011, 15:967-980.
98. Chavakis E., Urbich C., Dimmeler S. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol 2008, 45:514-522.
99. Tang Y.L., Zhu W., Cheng M., Chen L., Zhang J., Sun T., Kishore R., Phillips M.I., Losordo D.W., Qin G. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009, 104:1209-1216.
100. Al Kindi A.H., Asenjo J.F., Ge Y., Chen G.Y., Bhathena J., Chiu R.C., Prakash S., Shum-Tim D. Microencapsulation to reduce mechanical loss of microspheres: implications in myocardial cell therapy. Eur J Cardiothorac Surg 2011, 39:241-247.
101. Huang J., Zhang Z., Guo J., Ni A., Deb A., Zhang L., Mirotsou M., Pratt R.E., Dzau V.J. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 2010, 106:1753-1762.
102. Forte G., Pagliari S., Pagliari F., Ebara M., Di Nardo P., Aoyagi T. Towards the generation of patient-specific patches for cardiac repair. Stem Cell Rev 2013, 9:313-325.